Immune Pharmaceuticals reports additional Phase II data for bertilimumab in bullous pemphigoid

In September, Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) reported additional data from 6 patients with moderate to severe bullous pemphigoid in a Phase II trial showing that IV bertilimumab (CAT-213, iCo-008) led to a decline in the Bullous Pemphigoid Disease Area Index (BPDAI)

Read the full 420 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE